Phillips Medisize Enhances Inhalation Drug Delivery with Vectura Integration

In a significant development, Phillips Medisize announces the integration of Vectura, enhancing its capabilities in inhalation drug delivery. This strategic move amplifies Phillips Medisize’s offerings at the ongoing Respiratory Drug Delivery Conference, underscoring its dedication to advancing inhalation science and product innovation. The merger signifies a pivotal shift in the inhalation drug market, impacting both patients and pharmaceutical partners.

Phillips Medisize, a leader in drug delivery device design and production, has formally integrated Vectura into its operations. This union strengthens the company’s position in the inhaled product development market, adding depth to its suite of drug delivery solutions. Known for collaborating with leading pharmaceutical and medical technology companies, Phillips Medisize leverages over 60 years of expertise to bring innovative solutions to the health sector. The integration with Vectura not only expands its technological capabilities but also enhances its reach through a global supply chain. The ongoing Respiratory Drug Delivery Conference serves as a platform for Phillips Medisize to showcase this expanded prowess, emphasizing the importance of inhalation science in modern healthcare.